NEW
YORK, Jan. 23, 2025 /PRNewswire/ -- Baird
Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or
the "Company"), a leader in microwave ablation technology (MWA),
announced today that it will participate in the highly anticipated
Microcap Conference, set to take place at the Borgata Hotel in
Atlantic City, New Jersey, from
January 28 to January 30, 2025.
Baird Medical specializes in the design and development of
cutting-edge needles and apparatus for microwave ablation of
thyroid nodules. This minimally invasive treatment is an
alternative to traditional open neck surgery and offers significant
benefits for patients worldwide. With a dominant market presence in
China and FDA 510(k) clearance
achieved in November 2023, Baird
Medical is poised for continued growth and expansion in the global
healthcare landscape.
"We are excited to connect with investors and industry peers at
the Microcap Conference," said Haimei Wu, Chairwoman of Baird
Medical. "Our recent FDA clearance represents a pivotal milestone,
enabling us to bring our innovative solutions to patients in
the United States while leveraging
our expertise as a market leader in China. This event provides an excellent
platform to showcase our achievements and share our vision for the
future of minimally invasive treatment technologies."
The Microcap Conference is an annual gathering of microcap
company executives, institutional investors, and thought leaders.
It offers a dynamic forum for networking, presentations, and
discussions about emerging investment opportunities. Baird
Medical's leadership team will deliver presentations and engage in
one-on-one meetings with investors throughout the week.
Attendees and interested parties are encouraged to visit Baird
Medical's booth or schedule a meeting by contacting
maxm@bairdmed.com.
For additional information about Baird Medical and its
innovative microwave ablation technology, please visit
https://bairdmed.com/.
About Baird Medical
Baird Medical is a leading provider of minimally invasive
microwave ablation (MWA) technology, offering advanced treatment
solutions for conditions such as thyroid nodules, breast disease,
uterine fibroids, and liver cancer. A publicly traded company on
NASDAQ, Baird Medical is dedicated to enhancing patient care
through precision, efficiency, and safety in its innovative medical
devices. For more information, please
visit https://bairdmed.com/
Forward-Looking Statements:
This press release contains forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. Forward-looking statements are statements that are not
historical facts and generally relate to future events or Baird
Medical's future financial or operational performance. In some
cases, you can identify forward-looking statements by terminology
such as "may," "might," "will," "should," "expect," "intend,"
"plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue," or the negative of these terms or other
similar expressions.
These forward-looking statements are subject to risks,
uncertainties, and assumptions that could cause actual results or
outcomes to differ materially from those expressed or implied.
These statements are based on estimates and assumptions that, while
considered reasonable by Baird Medical and its management, are
inherently uncertain. Risks and uncertainties may emerge over time,
and it is not possible to anticipate all potential factors that
could affect Baird Medical's business and financial
performance.
Factors that could cause actual results to differ materially
include, but are not limited to: (1) the risk that Baird Medical
may not achieve its expansion goals in the United
States, China, or other markets; (2) changes in economic,
regulatory, or market conditions that impact Baird Medical's
operations; (3) the ability to realize anticipated benefits from
ongoing business initiatives or strategic transactions; (4)
regulatory developments and compliance with applicable laws; (5)
risks related to the development, commercialization, and market
acceptance of Baird Medical's products; and (6) other risks and
uncertainties detailed in Baird Medical's filings with
the SEC.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. Baird Medical undertakes no obligation to update or
revise forward-looking statements, whether as a result of new
information, future events, or otherwise, except as required by
law. All forward-looking statements in this press release are
qualified in their entirety by this cautionary statement.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-attend-microcap-conference-at-borgata-hotel-302356624.html
SOURCE BDMD
